论文部分内容阅读
目的 探讨腺病毒介导TNF α基因转染树突状细胞 (DCs)诱导抗肿瘤免疫的可能性。方法 用 10 0MOI的AdV TNF α和AdV pLpA(无外源基因 )分别感染小鼠DCs ,采用RNA酶保护实验检测其细胞因子的表达 ,同时用混合淋巴细胞试验分析其抗原提呈差异 ,然后将各实验组DCs分别免疫C5 7BL/ 6小鼠 ,10天后以不同剂量瘤细胞攻击小鼠以观察其保护效力。结果 DCTNF α组TNF α、IL 12、IL 18以及GM CSF表达量较对应组增高 ;体外混合淋巴细胞试验表明DCTNF α组抗原提呈功能增强 ;体外、体内特异性抗肿瘤实验均显示该型瘤苗具有良好的抗瘤作用。结论 该基因工程DCs可应用于肿瘤的免疫治疗
Objective To investigate the possibility of adenovirus-mediated TNFα gene transfection of dendritic cells (DCs) to induce anti-tumor immunity. Methods Mouse DCs were infected with 100 MOI of AdV TNF α and AdV pLpA (without exogenous genes). Cytokine expression was detected by RNase protection assay. The antigen presentation differences were analyzed by mixed lymphocyte assay. DCs of each experimental group were immunized with C57BL/6 mice respectively. After 10 days, mice were challenged with different doses of tumor cells to observe their protective efficacy. Results The expression levels of TNFα, IL 12, IL 18 and GM CSF in DCTNFα group were higher than that in the corresponding group. In vitro mixed lymphocyte test showed that the antigen presentation function of DCTNFα group was enhanced; specific antitumor experiments in vitro and in vivo showed that Seedlings have a good anti-tumor effect. Conclusion The genetically engineered DCs can be applied to tumor immunotherapy